Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Millendo Therapeutics stock | $2

Own Millendo Therapeutics stock in just a few minutes.

Fact checked

Millendo Therapeutics, Inc is a biotechnology business based in the US. Millendo Therapeutics shares (MLND) are listed on the NASDAQ and all prices are listed in US Dollars. Millendo Therapeutics employs 24 staff and has a market cap (total outstanding shares value) of USD$37.2 million.

How to buy shares in Millendo Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Millendo Therapeutics. Find the stock by name or ticker symbol: MLND. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Millendo Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Millendo Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Millendo Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Millendo Therapeutics share price

Use our graph to track the performance of MLND stocks over time.

Millendo Therapeutics shares at a glance

Information last updated 2020-12-09.
Latest market closeUSD$2
52-week rangeUSD$1.3 - USD$9.88
50-day moving average USD$1.6634
200-day moving average USD$1.8021
Wall St. target priceUSD$4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.865

Buy Millendo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Millendo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Millendo Therapeutics price performance over time

Historical closes compared with the close of $2 from 2020-12-09

1 week (2021-01-07) 23.46%
1 month (2020-12-17) -6.54%
3 months (2020-10-15) 15.61%
6 months (2020-07-15) 17.65%
1 year (2020-01-15) -75.06%
2 years (2019-01-15) -77.27%
3 years (2018-01-13) N/A
5 years (2016-01-15) 6.71

Millendo Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -48.49%
Return on equity TTM -98.63%
Profit margin 0%
Book value $2.06
Market capitalisation USD$37.2 million

TTM: trailing 12 months

Shorting Millendo Therapeutics shares

There are currently 635,794 Millendo Therapeutics shares held short by investors – that's known as Millendo Therapeutics's "short interest". This figure is 36.2% up from 466,754 last month.

There are a few different ways that this level of interest in shorting Millendo Therapeutics shares can be evaluated.

Millendo Therapeutics's "short interest ratio" (SIR)

Millendo Therapeutics's "short interest ratio" (SIR) is the quantity of Millendo Therapeutics shares currently shorted divided by the average quantity of Millendo Therapeutics shares traded daily (recently around 338188.29787234). Millendo Therapeutics's SIR currently stands at 1.88. In other words for every 100,000 Millendo Therapeutics shares traded daily on the market, roughly 1880 shares are currently held short.

However Millendo Therapeutics's short interest can also be evaluated against the total number of Millendo Therapeutics shares, or, against the total number of tradable Millendo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Millendo Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Millendo Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0337% of the tradable shares (for every 100,000 tradable Millendo Therapeutics shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Millendo Therapeutics.

Find out more about how you can short Millendo Therapeutics stock.

Millendo Therapeutics share dividends

We're not expecting Millendo Therapeutics to pay a dividend over the next 12 months.

Have Millendo Therapeutics's shares ever split?

Millendo Therapeutics's shares were split on a 1:15 basis on 10 December 2018. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Millendo Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Millendo Therapeutics shares which in turn could have impacted Millendo Therapeutics's share price.

Millendo Therapeutics overview

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site